Background: Amrubicin is a promising therapy for lung cancer, but is associated with a high
incidence of severe neutropenia. The present study assessed the utility of ABCB1 and NAD …

Chemotherapy-induced neutropenia is one of the major adverse events which results in the
reduction of chemotherapy. Doxorubicin is a substrate of the adenosine triphosphate …

Background Amrubicin hydrochloride (AMR) is a key agent for lung cancer. NADPH quinone
oxidoreductase 1 (NQO1) metabolizes the quinone structures contained in both amrubicin …

Introduction Amrubicin is a promising agent in the treatment of lung cancer, but predictive
biomarkers have not yet been described. NAD (P) H: quinone oxidoreductase 1 (NQO1) is …

Purpose To investigate the influence of ABCB1 polymorphisms on prognostic outcomes in
Chinese patients with de novo intermediate-risk acute myeloid leukemia (AML) and to …

Background Platinum-based doublets are the standard chemotherapy for lung cancer. The
identification of markers associated with drug toxicity may improve the success of the …

The aim of this study is to investigate the association of ABCB1 polymorphisms with
susceptibility to adult acute leukemia, and the influence of ABCB1 polymorphisms on the …

Objectives The classical multidrug resistance (MDR) gene MDR1 (ABCB1) encodes for the
drug efflux pump P‐glycoprotein (P‐gp). P‐gp expression is an adverse prognostic factor for …

Background: Neutropenia is the most common adverse event of breast cancer
chemotherapy which can be life threatening due to opportunistic infection, neutropenic …

The ABCB1 gene encodes for P-glycoprotein (P-gp), an efflux pump for a variety of
xenobiotics. The role of ABCB1 polymorphisms in acute myeloid leukemia (AML) outcomes …